Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Haemonetics Corporation is a global medical technology company specializing in blood and plasma management solutions. The company operates within the medical devices, biotechnology services, and healthcare technology industries, focusing on improving the quality, safety, and efficiency of blood-related therapies. Its core offerings support blood collection centers, plasma collection operators, and hospitals, with products designed to enhance donor yield, optimize clinical outcomes, and reduce healthcare system costs.
The company generates revenue primarily through proprietary medical devices, single‑use disposables, and software platforms tied to recurring customer usage. Haemonetics serves plasma collection organizations, blood banks, and acute‑care hospitals, with a strategic emphasis on long‑term customer relationships and consumables‑driven revenue. Founded in 1971, Haemonetics has evolved from a blood processing equipment manufacturer into a diversified, data‑enabled blood management company through internal innovation and targeted acquisitions.
Business Operations
Haemonetics operates through several core business segments: Plasma, Blood Center, Hospital, and Hemostasis Management. The Plasma segment is the company’s largest revenue driver and includes automated plasma collection systems, donor management software, and single‑use disposables sold to commercial plasma operators. The Blood Center segment focuses on whole blood and component collection systems used by nonprofit blood banks, while the Hospital segment provides cell salvage, transfusion management software, and blood conservation technologies used in surgical and critical care settings.
The Hemostasis Management segment includes vascular closure devices and diagnostic technologies that support interventional cardiology and electrophysiology procedures. Haemonetics generates revenue through a combination of capital equipment sales and recurring consumables, with a strong installed base supporting predictable cash flows. The company maintains manufacturing, R&D, and service operations across multiple regions and distributes products through a combination of direct sales forces and regional distributors.
Strategic Position & Investments
Haemonetics’ strategy centers on expanding its leadership in plasma collection while increasing its presence in hospital‑based and data‑driven clinical solutions. Growth initiatives include continued innovation in donor yield optimization, software analytics, and connected device platforms that integrate clinical data across customer operations. The company emphasizes recurring revenue models and long‑term contracts with large plasma operators as a core strategic advantage.
Notable acquisitions include Cardiva Medical, which expanded Haemonetics’ vascular closure portfolio, and OpSens Medical, which added pressure‑wire technology used in coronary physiology assessment. These investments reflect a broader push into interventional cardiology and hemostasis management markets. The company continues to invest in emerging technologies that combine medical devices with software, analytics, and workflow automation, although the long‑term financial impact of certain newer platforms remains data inconclusive based on available public sources.
Geographic Footprint
Haemonetics is headquartered in North America, with its corporate headquarters in the United States. The company maintains a significant operational presence across Europe, Asia‑Pacific, and Latin America, supporting both manufacturing and commercial activities. International markets represent a substantial portion of total revenue, particularly in plasma and hospital products.
The company’s global footprint includes direct sales operations in major healthcare markets and distribution partnerships in regions where direct presence is limited. Haemonetics’ technologies are used in more than 90 countries, giving it broad international exposure and influence in global blood and plasma supply chains.
Leadership & Governance
Haemonetics is led by an executive team focused on operational discipline, innovation, and long‑term value creation. The leadership emphasizes a strategy of technology differentiation, recurring revenue growth, and disciplined capital allocation aligned with shareholder interests.
Key executives include:
- Christopher A. Simon – President and Chief Executive Officer
- Aaron Tobin – Executive Vice President and Chief Financial Officer
- Dan Goldstein – Executive Vice President and Chief Operating Officer
- Gina A. Allen – Executive Vice President, Global Human Resources
The company is governed by an independent board of directors with experience across healthcare, medical devices, and global operations, supporting oversight of strategy, risk management, and regulatory compliance.